Omeros Corporation (OMER)
| Market Cap | 1.20B |
| Revenue (ttm) | 96.60M |
| Net Income (ttm) | -130.01M |
| Shares Out | 58.23M |
| EPS (ttm) | -2.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $19.23 |
| Previous Close | $19.50 |
| Change ($) | -0.27 |
| Change (%) | -1.38% |
| Day's Open | 19.58 |
| Day's Range | 19.18 - 19.61 |
| Day's Volume | 470,850 |
| 52-Week Range | 9.03 - 19.72 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan H...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (AS...
Omeros (OMER) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administ...
Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call Transcript
Omeros (OMER) delivered earnings and revenue surprises of 33.33% and 39.30%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein th...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, ...
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a...
The Omeros narsoplimab ship is finally coming in after long voyages in treacherous waters. Omeros' liquidity is improved but will likely remain challenging.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microa...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company's lead h...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-as...
OMER share price has been depressed over continued uncertainty regarding sales of their primary revenue-driver.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocu...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D.
Omeros (OMER) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe C...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug...
The biopharma announced the pricing of a public offering of common stock and debt offering.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common stock (t...
Omeros stock shot up more than 60% after the Seattle-based biotech company reported promising results from its COVID-19 drug treatment.
Omeros (OMER) delivered earnings and revenue surprises of 11.11% and -25.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has commenced concurrent underwritten public offerings of $125,000,000 of shares of its common st...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein th...
Omeros Corporation (NASDAQ: OMER) shares were galloping higher Monday after the biopharma announced results from a compassionate use study of its lead investigational human monoclonal antibody.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monoclonal antibody ta...
Two major catalysts on the horizon could send Omeros' stock soaring. What should investors think?
Today, we revisit Omeros. The company has two potential catalysts on the near term horizon and the stock is a good covered call candidate.
Omeros shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75 appeared firs...
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2020 Results - Earnings Call Transcript
Omeros (OMER) delivered earnings and revenue surprises of -2.50% and -23.88%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Omeros Corporation: The Thesis Was Playing Out Before COVID-19 Hit
The company reported full-year 2019 operating results and a separate update from the pipeline.
Omeros Corporation (OMER) CEO Greg Demopulos on Q4 2019 Results - Earnings Call Transcript
Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma
Single-arm trial data for narsoplimab isn't nearly as exciting as it used to be.
Shares of thinly-traded small-cap biopharma Omeros Corporation (NASDAQ: OMER) are advancing Wednesday following a positive readout from a pivotal Phase 3 study of its investigational asset nar...
Shares of Omeros Corp. OMER, +8.08% rallied 7% in morning trading on positive data for narsoplimab, its experimental therapy for a complication that can occur for patients undergoing stem cell...
Omeros: Bull Thesis Cracked And Bleeding But Still Intact
Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2019 Results - Earnings Call Transcript
Find out why these stocks missed out on the market rally.
About OMER
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic ... [Read more...]
| Industry Biotechnology | IPO Date Oct 8, 2009 |
| CEO Gregory Demopulos | Employees 258 |
| Stock Exchange NASDAQ | Ticker Symbol OMER |
Financial Performance
In 2019, Omeros's revenue was $111.81 million, an increase of 274.33% compared to the previous year's $29.87 million. Losses were -$84.49 million, -33.35% less than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for Omeros stock is "Buy." The 12-month stock price forecast is 34.50, which is an increase of 79.41% from the latest price.